Amicus Therapeut Financials
This page shows Amicus Therapeut (FOLD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 24 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Amicus Therapeut has an operating margin of 5.2%, meaning the company retains $5 of operating profit per $100 of revenue. This results in a moderate score of 34/100, indicating healthy but not exceptional operating efficiency. This is up from 4.7% the prior year.
Amicus Therapeut's revenue surged 20.0% year-over-year to $634.2M, reflecting rapid business expansion. This strong growth earns a score of 67/100.
Amicus Therapeut carries a low D/E ratio of 1.43, meaning only $1.43 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 73/100, indicating a strong balance sheet with room for future borrowing.
Amicus Therapeut's current ratio of 2.84 indicates adequate short-term liquidity, earning a score of 54/100. The company can meet its near-term obligations, though with limited headroom.
Amicus Therapeut has a free cash flow margin of 4.7%, earning a moderate score of 37/100. The company generates positive cash flow after capital investments, but with room for improvement.
Amicus Therapeut generates a -9.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -28.9% the prior year.
Amicus Therapeut scores 1.28, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.5B) relative to total liabilities ($675.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Amicus Therapeut passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Amicus Therapeut generates $-1.22 in operating cash flow ($33.1M OCF vs -$27.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Amicus Therapeut earns $0.7 in operating income for every $1 of interest expense ($32.8M vs $46.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Amicus Therapeut generated $634.2M in revenue in fiscal year 2025. This represents an increase of 20.0% from the prior year.
Amicus Therapeut's EBITDA was $40.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 20.4% from the prior year.
Amicus Therapeut reported -$27.1M in net income in fiscal year 2025. This represents an increase of 51.7% from the prior year.
Amicus Therapeut earned $-0.09 per diluted share (EPS) in fiscal year 2025. This represents an increase of 50.0% from the prior year.
Cash & Balance Sheet
Amicus Therapeut generated $29.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 179.7% from the prior year.
Amicus Therapeut held $214.0M in cash against $392.7M in long-term debt as of fiscal year 2025.
Amicus Therapeut had 314M shares outstanding in fiscal year 2025. This represents an increase of 4.6% from the prior year.
Margins & Returns
Amicus Therapeut's gross margin was 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.
Amicus Therapeut's operating margin was 5.2% in fiscal year 2025, reflecting core business profitability. This is up 0.5 percentage points from the prior year.
Amicus Therapeut's net profit margin was -4.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.3 percentage points from the prior year.
Amicus Therapeut's ROE was -9.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 19.0 percentage points from the prior year.
Capital Allocation
Amicus Therapeut invested $135.8M in research and development in fiscal year 2025. This represents an increase of 24.2% from the prior year.
Amicus Therapeut invested $3.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.2% from the prior year.
FOLD Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $185.2M+9.6% | $169.1M+9.3% | $154.7M+23.5% | $125.2M-16.3% | $149.7M+5.8% | $141.5M+11.7% | $126.7M+14.7% | $110.4M |
| Cost of Revenue | $26.5M+36.4% | $19.5M+27.9% | $15.2M+30.1% | $11.7M-21.2% | $14.8M+11.7% | $13.3M+17.9% | $11.3M-17.0% | $13.6M |
| Gross Profit | $158.7M+6.1% | $149.6M+7.3% | $139.5M+22.8% | $113.6M-15.8% | $134.9M+5.2% | $128.2M+11.1% | $115.4M+19.2% | $96.8M |
| R&D Expenses | $23.7M+1.4% | $23.4M-61.5% | $60.8M+118.6% | $27.8M-7.8% | $30.2M+15.4% | $26.2M+6.0% | $24.7M-12.9% | $28.3M |
| SG&A Expenses | $117.1M+30.0% | $90.0M+6.5% | $84.5M-7.9% | $91.8M+6.0% | $86.7M+15.4% | $75.1M+2.1% | $73.6M-16.4% | $88.0M |
| Operating Income | $15.9M-53.5% | $34.3M+461.7% | -$9.5M-19.1% | -$8.0M-149.8% | $16.0M-26.3% | $21.7M+44.7% | $15.0M+154.0% | -$27.7M |
| Interest Expense | $11.4M-2.4% | $11.7M+1.3% | $11.6M+1.0% | $11.5M-4.2% | $12.0M-5.8% | $12.7M+1.4% | $12.5M+0.6% | $12.4M |
| Income Tax | $1.5M-91.4% | $17.0M+223.9% | $5.2M+43.9% | $3.6M+153.5% | -$6.8M-150.4% | $13.5M-14.5% | $15.8M+226.8% | $4.8M |
| Net Income | $1.7M-90.2% | $17.3M+170.9% | -$24.4M-12.6% | -$21.7M-247.1% | $14.7M+319.0% | -$6.7M+57.1% | -$15.7M+67.6% | -$48.4M |
| EPS (Diluted) | N/A | $0.06+175.0% | $-0.08-14.3% | $-0.07 | N/A | $-0.02+60.0% | $-0.05+68.8% | $-0.16 |
FOLD Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $949.9M+9.3% | $868.8M+6.6% | $815.3M+3.2% | $789.8M+0.6% | $785.0M-0.2% | $786.6M+4.9% | $749.5M+3.8% | $721.8M |
| Current Assets | $676.2M+13.8% | $594.1M+10.4% | $538.0M+5.3% | $510.8M+1.2% | $504.7M+1.3% | $498.5M+8.0% | $461.7M+7.1% | $431.2M |
| Cash & Equivalents | $214.0M+12.3% | $190.6M+20.1% | $158.7M-12.6% | $181.7M-15.0% | $213.8M-8.5% | $233.6M+11.6% | $209.3M-0.2% | $209.8M |
| Inventory | $228.8M+28.6% | $177.9M+14.9% | $154.9M+17.0% | $132.4M+11.5% | $118.8M+3.0% | $115.3M+41.8% | $81.3M+33.8% | $60.8M |
| Accounts Receivable | $115.3M+1.3% | $113.8M+7.5% | $105.8M+19.8% | $88.3M-12.6% | $101.1M+3.1% | $98.1M+15.1% | $85.2M+11.4% | $76.4M |
| Goodwill | $197.8M0.0% | $197.8M0.0% | $197.8M0.0% | $197.8M0.0% | $197.8M0.0% | $197.8M0.0% | $197.8M0.0% | $197.8M |
| Total Liabilities | $675.6M+5.8% | $638.4M+4.5% | $611.0M+2.5% | $596.3M+0.9% | $591.0M-2.8% | $607.7M-1.5% | $617.0M+4.4% | $591.1M |
| Current Liabilities | $237.8M+19.6% | $198.9M+18.7% | $167.6M+9.7% | $152.9M+2.8% | $148.7M-6.0% | $158.1M-5.9% | $168.1M+18.3% | $142.1M |
| Long-Term Debt | $392.7M+0.2% | $392.0M+0.2% | $391.3M+0.2% | $390.7M+0.2% | $390.1M+0.2% | $389.5M+0.1% | $388.9M+0.1% | $388.4M |
| Total Equity | $274.2M+19.0% | $230.4M+12.8% | $204.3M+5.6% | $193.6M-0.3% | $194.0M+8.5% | $178.8M+34.9% | $132.5M+1.4% | $130.7M |
| Retained Earnings | -$2.8B+0.1% | -$2.8B+0.6% | -$2.8B-0.9% | -$2.8B-0.8% | -$2.7B+0.5% | -$2.8B-0.2% | -$2.7B-0.6% | -$2.7B |
FOLD Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $16.3M-54.4% | $35.7M+234.4% | -$26.5M-441.9% | $7.8M+298.1% | -$3.9M+83.0% | -$23.0M-201.2% | $22.7M+176.4% | -$29.7M |
| Capital Expenditures | $299K-21.7% | $382K-84.1% | $2.4M+1033.5% | $212K-26.4% | $288K-19.1% | $356K-67.6% | $1.1M-39.4% | $1.8M |
| Free Cash Flow | $16.0M-54.8% | $35.3M+221.9% | -$28.9M-483.4% | $7.5M+279.5% | -$4.2M+82.0% | -$23.3M-208.0% | $21.6M+168.5% | -$31.5M |
| Investing Cash Flow | -$6.5M-399.9% | -$1.3M+77.5% | -$5.8M+82.4% | -$32.9M-61.1% | -$20.4M-159.5% | $34.3M+255.9% | -$22.0M-391.6% | $7.5M |
| Financing Cash Flow | $14.0M+1163.6% | -$1.3M-229.8% | -$400K+96.6% | -$11.7M-1166.5% | $1.1M-94.0% | $18.2M+2222.5% | -$857K+93.6% | -$13.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FOLD Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.7%-2.8pp | 88.5%-1.7pp | 90.2%-0.5pp | 90.7%+0.6pp | 90.1%-0.5pp | 90.6%-0.5pp | 91.1%+3.4pp | 87.7% |
| Operating Margin | 8.6%-11.7pp | 20.3%+26.4pp | -6.1%+0.2pp | -6.3%-17.0pp | 10.7%-4.6pp | 15.3%+3.5pp | 11.8%+36.9pp | -25.1% |
| Net Margin | 0.9%-9.3pp | 10.2%+26.0pp | -15.8%+1.5pp | -17.3%-27.2pp | 9.8%+14.6pp | -4.8%+7.6pp | -12.4%+31.5pp | -43.9% |
| Return on Equity | 0.6%-6.9pp | 7.5%+19.5pp | -11.9%-0.7pp | -11.2%-18.8pp | 7.6%+11.4pp | -3.8%+8.1pp | -11.8%+25.2pp | -37.0% |
| Return on Assets | 0.2%-1.8pp | 2.0%+5.0pp | -3.0%-0.2pp | -2.8%-4.6pp | 1.9%+2.7pp | -0.9%+1.2pp | -2.1%+4.6pp | -6.7% |
| Current Ratio | 2.84-0.1 | 2.99-0.2 | 3.21-0.1 | 3.34-0.1 | 3.39+0.2 | 3.15+0.4 | 2.75-0.3 | 3.03 |
| Debt-to-Equity | 1.43-0.3 | 1.70-0.2 | 1.92-0.1 | 2.020.0 | 2.01-0.2 | 2.18-0.8 | 2.93-0.0 | 2.97 |
| FCF Margin | 8.6%-12.3pp | 20.9%+39.6pp | -18.7%-24.7pp | 6.0%+8.8pp | -2.8%+13.7pp | -16.5%-33.5pp | 17.1%+45.6pp | -28.5% |
Similar Companies
Frequently Asked Questions
What is Amicus Therapeut's annual revenue?
Amicus Therapeut (FOLD) reported $634.2M in total revenue for fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Amicus Therapeut's revenue growing?
Amicus Therapeut (FOLD) revenue grew by 20% year-over-year, from $528.3M to $634.2M in fiscal year 2025.
Is Amicus Therapeut profitable?
No, Amicus Therapeut (FOLD) reported a net income of -$27.1M in fiscal year 2025, with a net profit margin of -4.3%.
What is Amicus Therapeut's EBITDA?
Amicus Therapeut (FOLD) had EBITDA of $40.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Amicus Therapeut have?
As of fiscal year 2025, Amicus Therapeut (FOLD) had $214.0M in cash and equivalents against $392.7M in long-term debt.
What is Amicus Therapeut's gross margin?
Amicus Therapeut (FOLD) had a gross margin of 88.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Amicus Therapeut's operating margin?
Amicus Therapeut (FOLD) had an operating margin of 5.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Amicus Therapeut's net profit margin?
Amicus Therapeut (FOLD) had a net profit margin of -4.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Amicus Therapeut's return on equity (ROE)?
Amicus Therapeut (FOLD) has a return on equity of -9.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Amicus Therapeut's free cash flow?
Amicus Therapeut (FOLD) generated $29.8M in free cash flow during fiscal year 2025. This represents a 179.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Amicus Therapeut's operating cash flow?
Amicus Therapeut (FOLD) generated $33.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Amicus Therapeut's total assets?
Amicus Therapeut (FOLD) had $949.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Amicus Therapeut's capital expenditures?
Amicus Therapeut (FOLD) invested $3.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Amicus Therapeut spend on research and development?
Amicus Therapeut (FOLD) invested $135.8M in research and development during fiscal year 2025.
What is Amicus Therapeut's current ratio?
Amicus Therapeut (FOLD) had a current ratio of 2.84 as of fiscal year 2025, which is generally considered healthy.
What is Amicus Therapeut's debt-to-equity ratio?
Amicus Therapeut (FOLD) had a debt-to-equity ratio of 1.43 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Amicus Therapeut's return on assets (ROA)?
Amicus Therapeut (FOLD) had a return on assets of -2.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Amicus Therapeut's Altman Z-Score?
Amicus Therapeut (FOLD) has an Altman Z-Score of 1.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Amicus Therapeut's Piotroski F-Score?
Amicus Therapeut (FOLD) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Amicus Therapeut's earnings high quality?
Amicus Therapeut (FOLD) has an earnings quality ratio of -1.22x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Amicus Therapeut cover its interest payments?
Amicus Therapeut (FOLD) has an interest coverage ratio of 0.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Amicus Therapeut?
Amicus Therapeut (FOLD) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.